Search - tctmd.com

Displaying 641 - 660 of 762

Sort: Relevancy | Date

News Conference News

PEPCAD-DES: Drug-Coated Balloon Better Than Uncoated Balloon for DES Restenosis

November 27, 2011

News Conference News

RIBS III: Alternative DES Best Bet for DES In-Stent Restenosis

November 22, 2011

News Conference News

Drug-Eluting Balloons an Option for Patients with BMS Restenosis, High Bleeding Risk

November 17, 2011

News Conference News

‘Judicious Use’ of DES in Low-Risk Patients Could Save Over $200 Million per Year

November 16, 2011

News Conference News

Experimental System Targets Drugs to AAA Wall via Stent Graft

November 15, 2011

News Industry News

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

November 13, 2011

News Conference News

ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients

November 13, 2011

News Industry News

Rotablation does not improve efficacy of drug-eluting stents in complex calcified coronary lesions

November 10, 2011

News Industry News

Polymer-free drug eluting stents result in lower in-stent late loss

November 10, 2011

News Industry News

Paclitaxel-coated balloon angioplasty demonstrates superior results

November 10, 2011

News Industry News

Head-to-head comparison of two second generation drug-eluting coronary stents demonstrates non-inferiority

November 10, 2011

News Industry News

Clinical trial establishes non-inferiority of drug-eluting stent with a bioabsorbable polymer

November 10, 2011

News Industry News

Use of drug-eluting balloons with bare metal stents do not show superiority over drug-eluting stents

November 09, 2011

News Industry News

Tryton Announces Successful Live Case Transmission at TCT Conference in San Francisco

November 09, 2011

News Industry News

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

November 09, 2011

News Industry News

Low CV Event Rate Prompts Closure of Prasugrel Trial

November 09, 2011

News Industry News

BIOTRONIK Announces Positive Results for Pantera Lux Paclitaxel Releasing Balloon

November 09, 2011

News Industry News

Bayer HealthCare's Cotavance Drug Eluting Balloon With Paccocath Technology Reduced Five-Year Target Lesion Revascularization Rates

November 09, 2011

News Industry News

Scripps Health and The Medicines Company Announce Late Breaking BRIDGE Trial Results Presented at TCT

November 08, 2011

News Industry News

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

November 08, 2011

Advertisement

PEPCAD-DES: Drug-Coated Balloon Better Than Uncoated Balloon for DES Restenosis

RIBS III: Alternative DES Best Bet for DES In-Stent Restenosis

Drug-Eluting Balloons an Option for Patients with BMS Restenosis, High Bleeding Risk

‘Judicious Use’ of DES in Low-Risk Patients Could Save Over $200 Million per Year

Experimental System Targets Drugs to AAA Wall via Stent Graft

REMEDEE Study Meets Primary Endpoint: OrbusNeich’s Combo™ Dual Therapy Stent Is Non-Inferior to DES

ISAR-REACT 4: Bivalirudin Reduces Major Bleeding in NSTEMI Patients

Rotablation does not improve efficacy of drug-eluting stents in complex calcified coronary lesions

Polymer-free drug eluting stents result in lower in-stent late loss

Paclitaxel-coated balloon angioplasty demonstrates superior results

Head-to-head comparison of two second generation drug-eluting coronary stents demonstrates non-inferiority

Clinical trial establishes non-inferiority of drug-eluting stent with a bioabsorbable polymer

Use of drug-eluting balloons with bare metal stents do not show superiority over drug-eluting stents

Tryton Announces Successful Live Case Transmission at TCT Conference in San Francisco

OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011

Low CV Event Rate Prompts Closure of Prasugrel Trial

BIOTRONIK Announces Positive Results for Pantera Lux Paclitaxel Releasing Balloon

Bayer HealthCare's Cotavance Drug Eluting Balloon With Paccocath Technology Reduced Five-Year Target Lesion Revascularization Rates

Scripps Health and The Medicines Company Announce Late Breaking BRIDGE Trial Results Presented at TCT

Risk of late stent thrombosis continues for up to seven years in patients with first generation drug-eluting stents; risk factors identified

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content